Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLANCTON: Early omega-3 fatty acid infusion in predicted severe acute pancreatitis
2023-505220-57-03Phase 3Authorised
- Sponsor
- Radboud University Medical Center
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in acute pancreatitis (AP) comparing Omegaven infusion with Control (placebo or standard of care) (2 arms). Primary endpoint: Composite of new organ failure and mortality at 180 days. Planned start Nov 2023; status: authorised.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
acute pancreatitis (AP)
Beyond the preview
Go deeper on 2023-505220-57-03.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505220-57-03.